2amane K, lndalao IL, Chida J, et al. Diisopropylamine dichloro- acetate, a novel pyruvate dehydrogenase kinase 4 inhibitor, as a potential therapeutic agent for metabolic disorders and multiorgan failure in severe influenza [ J ]. PLoS One, 2014,9 (5) : e98032. 被引量：1
3Basova NE, Rozengrart EV. How the various substrates activate the process of enzymatic hydrolysis by different cholinesterases [ J ]. Zh Evol Biokhim Fiziol, 2010,46(6) :485-488. 被引量：1
4Ng CS, Hasnat A, A1 Maruf A, et al. N-acetyltransferase 2 ( NAT2 ) genotype as a risk factor for development of drug-inducedliver injury relating to antituberculosis drug treatment in a mixed- ethnicity patient group [ J ]. Eur J Clin Pharmacol, 2014,70 (9) : 1079-1086. 被引量：1
5Devarbhavi I-I, Andrade RJ. Drug-induced liver injury due to anti- mierobials, central nervous system agents, and nonsteroidal anti- inflammatory drugs[ J]. Semin Liver Dis, 2014,34(2) : 145-161. 被引量：1
6Huang YS. Recent progress in genetic variation and risk of antitu- berculosis drug-induced liver injury [ J ]. J Chin Med Assoc, 2014,77(4) :169-173. 被引量：1
7Forget E J, Menzies D. Adverse reactions to first-line antitubercu- losis drugs[J]. Expert Opin Drug Saf, 2006,5(2) :231-249. 被引量：1
8Roy PD, Majumder M, Roy B. Pharmacogenomics of anti-TB drugs- related hepatotoxicity[J]. Pharmaeogenomies, 2008,9(3) :311-321. 被引量：1
9Yew WW, Leung CC. uttitubereulosis drugs and hepatotoxieity [ J ]. Respirology, 2006,11 (6) :699-707. 被引量：1
10Agal S, Baijal R, Pramanik S, et al. Monitoring and management of antitubereulosis drug induced hepatotoxieity[ J]. J Gastroentero] Hepatol, 2005,20( 11 ) :1745-1752. 被引量：1
